Earnings ·
Entera Bio Ltd. announced its financial results for the three months ended June 30, 2026, reporting a net loss of $7.3…
ENTXWEntera Bio Ltd.
Entera Bio Ltd. announced its financial results for the three months ended June 30, 2026, reporting a net loss of $7.3 million ($0.14 per share) compared to $2.7 million in the prior year period. The company also disclosed key business updates, including positive FDA feedback on a planned 12-month Phase 3 registrational study for EB613, an oral anabolic tablet for osteoporosis, with initiation expected in late 2026 and topline data anticipated in the second half of 2028. Additionally, Entera reported that it oversubscribed a $275 million private placement led by BVF Partners in July 2026, which will fund EB613 through NDA submission and extend its cash runway into 2030. The company is developing oral peptide therapies for unmet medical needs.